Data collected included age; sex; underlying diseases (diabetes mellitus, malignancy, central nervous system disorders, chronic renal failure, liver disease, human immunodeficiency virus, valvular heart disease, congestive heart failure in the previous 14 days, presence of intravascular prosthetic material, chronic obstructive pulmonary disease, and previous myocardial infarction); risk factors (alcoholism, current smoking, drug abuse, steroid treatment, central venous catheters, and indwelling urinary tract catheter); type of ICP (percutaneous transluminal coronary angioplasty [PTCA], diagnostic cardiac catheterization, or electrophysiologic studies); priority of the ICP (urgent or not); procedure variables (duration of the procedure, number of punctures, and number of days the sheath was left in place); complications and outcome during or after ICP (fever, chills, vascular lesion, neurologic lesion, hematoma at the site of puncture, primary BSI, catheter-related BSI, urosepsis, pneumonia, meningitis, endocarditis, shock, intensive care unit admission, and death); analytical data (white blood cell count, left deviation, platelet count); microorganism identified from blood cultures (gram-positive, gram-negative, or polymicrobial); duration of hospital stay; and empirical treatment (adequate or inadequate). Antimicrobial therapy was considered adequate if 1 or more antimicrobial agents with in vitro activity against the corresponding isolate were administered for a minimum of 5 days. Death was attributed to the infectious process if the patient died within 10 days of the bacteremic episode with a clinical course suggesting persistent infection; it was always attributed if the patient died during the phase of acute infection and death could not be clearly attributed to any other cause.